COMPARISON OF DISEASE STATUS AND OUTCOMES OF PATIENTS WITH PSORIATIC ARTHRITIS (PSA) RECEIVING ADALIMUMAB OR ETANERCEPT MONOTHERAPY IN EUROPE

被引：0
|
作者：
Narayanan, S. [1 ]
Lu, Y. [2 ]
Hutchings, R. [2 ]
Baynton, E. [2 ]
机构：
[1] Ipsos Healthcare, Columbia, MD USA
[2] Ipsos Healthcare, London, England
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.2574
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMS4
引用
收藏
页码：A373 / A373
页数：1
相关论文
共 50 条
  • [1] COMPARISON OF DISEASE STATUS AND OUTCOMES OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA) RECEIVING ADALIMUMAB OR ETANERCEPT MONOTHERAPY IN EUROPE
    Narayanan, S.
    Lu, Y.
    Hutchings, R.
    Baynton, E.
    Hautamaki, E.
    VALUE IN HEALTH, 2014, 17 (07) : 374 - 374
  • [2] COMPARISON OF DISEASE STATUS AND OUTCOMES OF PATIENTS WITH ANKYLOSING SPONDYLITIS (AS) RECEIVING ADALIMUMAB OR ETANERCEPT MONOTHERAPY IN EUROPE
    Narayanan, S.
    Lu, Y.
    Hutchings, R.
    Baynton, E.
    VALUE IN HEALTH, 2014, 17 (07) : A522 - A523
  • [3] COMPARISON OF DISEASE STATUS AND OUTCOMES OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA) RECEIVING ADALIMUMAB OR ETANERCEPT MONOTHERAPY IN THE UNITED STATES (US)
    Narayanan, S.
    Lu, Y.
    Hutchings, R.
    Baynton, E.
    VALUE IN HEALTH, 2015, 18 (03) : A154 - A1555
  • [4] COMPARISON OF DISEASE STATUS AND OUTCOMES OF PATIENTS WITH ANKYLOSING SPONDYLITIS (AS) RECEIVING ADALIMUMAB OR ETANERCEPT MONOTHERAPY IN THE UNITED STATES (US)
    Narayanan, S.
    Lu, Y.
    Hutchings, R.
    Graham, C. M.
    Baynton, E.
    VALUE IN HEALTH, 2015, 18 (03) : A292 - A293
  • [5] Maintenance of remission and monotherapy status over 66 months in patients with psoriatic arthritis receiving etanercept
    de Vlam, K.
    Bruhwyler, J.
    Boone, C.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (06) : 1094 - 1097
  • [6] INDIRECT COMPARISON OF ADALIMUMAB VERSUS ETANERCEPT FOR THE TREATMENT OF PSORIATIC ARTHRITIS
    Kirson, N.
    Rao, S.
    Birnbaum, H. G.
    Kantor, E.
    Wei, R.
    Cifaldi, M.
    VALUE IN HEALTH, 2011, 14 (03) : A129 - A130
  • [7] Outcomes in Patients with Rheumatoid Arthritis Initiating Monotherapy with Etanercept, Adalimumab, or Janus Kinase Inhibitors
    Pappas, Dimitrios
    O'Brien, Jacqueline
    Kelleman, Mike
    Guo, Lin
    Shan, Ying
    Baker, Joshua
    Kricorian, Greg
    Stryker, Scott
    Collier, David
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 2798 - 2800
  • [8] COMPARISON OF DISEASE STATUS AND OUTCOMES OF PATIENTS WITH PSORIATIC ARTHRITIS (PSA) RECEIVING THEIR FIRST BIOLOGIC IN UK, GERMANY, FRANCE, ITALY AND SPAIN (5EU)
    Narayanan, S.
    Lu, Y.
    Hutchings, R.
    Baskett, A.
    VALUE IN HEALTH, 2013, 16 (03) : A219 - A219
  • [9] Psoriasis outcomes in a randomized trial of etanercept and methotrexate as monotherapy or in combination in patients with psoriatic arthritis
    Merola, Joseph F.
    Gottlieb, Alice B.
    Mease, Philip
    Strand, Vibeke
    Kavanaugh, Arthur
    Helliwell, Philip
    Liu, Lyrica
    Chung, James B.
    Kricorian, Gregory
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB118 - AB118
  • [10] THE IMPACT OF PSORIASIS SEVERITY ON OUTCOMES AMONG PSORIATIC ARTHRITIS PATIENTS RECEIVING ADALIMUMAB
    不详
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1850 - 1851
12345